# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.
Verastem (NASDAQ:VSTM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.94) by...
HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.
RBC Capital analyst Gregory Renza reiterates Verastem (NASDAQ:VSTM) with a Outperform and maintains $32 price target.
Verastem (NASDAQ:VSTM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.62) by...
Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib ...
The company said it remains on track to begin submission of an NDA to the FDA for Accelerated Approval of this combination in t...